Products and
Pipeline

Overview^1-2

CAR T cells which produce IL-7 and CCL19 can generate T cell zone in the tumor microenvironment, leading to potent anti-tumor effects in solid tumors

MOA³

Using retrovirus technology, a patient's T cells are transfected with a GPC3-targeting CAR gene and the genes that encode for IL-7 and CCL19

- These enhancements result in a novel CAR T therapy with trafficking and survival for solid tumors

- Direct cytotoxicity is mediated by GPC3-specific CAR T cells

- IL-7 and CCL19 production provides an armoring effect on CAR T cells, enhances host T cell responses, and induces long-term immune memory

Clinical Trials

Study Name

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-102 in Adult Patients With GPC3-Expressing Previously Treated Solid Tumors

References

1. Adachi K, et al. Nat Biotechnol. 2018;36:346-351.

2. Takeda, Data on file.

3. PRIME CAR-T. Noile-Immune Biotech website. Accessed April 27, 2021. https://www.noile-immune.com/en/Our_Science/prime_car-t.html.

Disclaimers

*Collaboration with Noile-Immune Biotech.